Abstract
Background
Tilmicosin is a veterinary antibiotic with significant human toxicity at doses commonly used in animals, but the parenteral dose-response relationship has not been well characterized.
Methods
Human exposures to tilmicosin in the database of the American Association of Poison Control Centers (AAPCC) from 2001 to 2005 were analyzed for demographic associations, exposure dose, clinical effects and outcomes.
Results
Over the 5-year period, there were 1,291 single-substance human exposures to tilmicosin. The mean age was 39.1 years, and 80% were male. By route there were 768 (54%) parenteral exposures. Patients with parenteral exposures had a significantly increased likelihood of being seen at a healthcare facility, admission, and admission to an ICU. With nonparenteral exposure, most had no clinical effects or minor effects, and there were no major effects or deaths. With parenteral exposure, moderate effects occurred in 46 (6%), major effects in 2 (0.3%) and there were 4 (0.5%) deaths, two of which were suicides. A dose-response relationship could be demonstrated. Clinical effect durations of up to a week occurred at even the lowest dose range.
Conclusions
Over 250 cases of human tilmicosin exposure are reported to poison centers per year and over 150 of those are parenteral. Most exposures produce no or minor effects, but fatalities have occurred with parenteral exposure. The case fatality rate in parenteral exposures is 10 times the case fatality rate for all human exposures in the AAPCC database. Significant adverse and prolonged effects are reported at parenteral doses <0.5 mL, suggesting that all parenteral exposures should be referred for healthcare facility evaluation.
Keywords: tilmicosin, dose-response, parenteral exposure
Full Text
The Full Text of this article is available as a PDF (242.5 KB).
Footnotes
There was no outside funding of any kind used for this study.
References
- 1.Seifert SA, Jacobitz K. TESS-based characterization of human tilmicosin exposures and the dose-response relationship in parenteral exposures. Clin Toxicol (Phila) 2005;43(6):735–736. [Google Scholar]
- 2.Modric S, Webb AI, Derendorf H. Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther. 1998;21:444–452. doi: 10.1046/j.1365-2885.1998.00177.x. [DOI] [PubMed] [Google Scholar]
- 3.Forrester MB. Human exposures to tilmicosin reported to poison centers, Texas, 1998–2003. Hum Exp Toxicol. 2005;24:275–278. doi: 10.1191/0960327105ht516oa. [DOI] [PubMed] [Google Scholar]
- 4.Veenhuizen MF, Wright TJ, McManus RF, Owens JG. Analysis of reports of human exposure to Micotil 300 (tilmicosin injection) J Am Vet Med Assoc. 2006;229(11):1737–1742. doi: 10.2460/javma.229.11.1737. [DOI] [PubMed] [Google Scholar]
- 5.McGuigan MA. Human exposures to tilmicosin (MICOTIL) Vet Hum Toxicol. 1994;36(4):306–308. [PubMed] [Google Scholar]
- 6.Jordan WH, Byrd RA, Cochrane RL, et al. A review of the toxicology of the antibiotic MICOTIL 300. Vet Hum Toxicol. 1993;35(2):151–158. [PubMed] [Google Scholar]
- 7.Main BW, Means JR, Rinkema LE, et al. Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine in conscious unrestrained dogs. J Vet Pharmacol Ther. 1996;19:225–32. doi: 10.1111/j.1365-2885.1996.tb00042.x. [DOI] [PubMed] [Google Scholar]
- 8.Tamargo J, De Miguel B, Tejerina MT. A comparison of josamycin with macrolides and related antibiotics on isolated rat atria. Eur J Pharmacol. 1982;80:285–293. doi: 10.1016/0014-2999(82)90073-5. [DOI] [PubMed] [Google Scholar]
- 9.Main BW, Clark JO, Tucker TJ, Bricker GG, Miller CD, Holdsworth DL, Adams St, Strnat CA. Attenuation of tilmicosin cardiotoxicity with calcium chloride infusion in conscious beagle dogs. Clin Toxicol. 2005;43(6):695–695. [Google Scholar]
- 10.Wakabayashi K, Yamada S. Effects of several macrolide antibiotics on blood pressure of dogs. Japan J Pharmacol. 1972;22:799–807. doi: 10.1254/jjp.22.799. [DOI] [PubMed] [Google Scholar]
- 11.Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med. 1990;89(2):235–238. doi: 10.1016/0002-9343(90)90305-W. [DOI] [PubMed] [Google Scholar]
- 12.Kuffner EK, Dart RC. Death following intravenous injection of Micotil 300. J Tox Clin Tox. 1996;34:574–574. [Google Scholar]
- 13.VonEssen S, Spencer J, Hass B, et al. Unintentional human exposure to tilmocosin (Micotil® 300) J Toxicol/Clin Toxicol. 2003;41(3):229–233. doi: 10.1081/clt-120021103. [DOI] [PubMed] [Google Scholar]